Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-07-22 M&A Activity
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi va acquérir Vicebio et enrichir son pipeline de vaccins respiratoires
M&A Activity Classification · 98% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate action: Sanofi's agreement to acquire Vicebio Ltd. It details the strategic rationale (acquiring a respiratory vaccine candidate and the 'Molecular Clamp' technology), financial terms ($1.15 billion initial payment plus milestones), and expected closing timeline (Q4 2025). This type of announcement, detailing a major transaction like an acquisition or merger proposal, aligns perfectly with the definition of M&A Activity (TAR). It is not an Earnings Release (ER) as it focuses on M&A, not periodic financial results. It is not a Call Transcript (CT) or Investor Presentation (IP) as it is a formal press release format. It is not a comprehensive Annual Report (10-K) or Interim Report (IR). Therefore, the most appropriate classification is TAR (M&A Activity).
2025-07-22 French
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
M&A Activity Classification · 100% confidence The document is a press release announcing that Sanofi has entered into an agreement to acquire Vicebio Ltd. It details the strategic rationale, the technology involved, and the financial terms of the transaction (upfront payment and milestone payments). This fits the definition of M&A activity (Code: TAR).
2025-07-22 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is explicitly titled "Disclosure of trading in own shares" and contains detailed tables listing the purchase of Sanofi's own shares over a specific period (14 July 2025 to 18 July 2025), including volume, price, and broker information. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2025-07-21 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares) and contains detailed tables listing daily aggregated and individual transactions involving the company buying back its own shares between July 14, 2025, and July 18, 2025. This activity directly corresponds to the definition of a company buying back or selling its own shares, which maps precisely to the 'Transaction in Own Shares' category.
2025-07-21 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Sanofi, with the SEC. It references a press release about the completion of an acquisition, attached as Exhibit 99.1. The document itself is short (1612 characters) and primarily serves as a regulatory filing to report the press release. It does not contain detailed financial data or the full acquisition documents, but rather announces the event. According to the rules, such filings that report events or press releases without substantive financial or detailed report content are classified as Regulatory Filings (RNS).
2025-07-18 English
Communiqué de presse : Sanofi finalise l’acquisition de Blueprint Medicines
M&A Activity Classification · 100% confidence The document is a press release from Sanofi announcing the finalization of its acquisition of Blueprint Medicines Corporation. It details the completion of the tender offer, the merger process, the financial implications, and the strategic rationale for the acquisition. This falls squarely under M&A activity (mergers and acquisitions).
2025-07-18 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.